Rapid Response, Unexpected Risk: A ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Case with Lazarus Syndrome and Fatal Thrombosis

A 57-year-old woman with a ROS1-rearranged NSCLC patient demonstrated a Lazarus response to crizotinib but later developed recurrent pulmonary embolism (PE) with right ventricular (RV) failure. This incident highlights the potential crizotinib-related thrombotic risk and the need for appropriate monitoring of vascular complications, particularly in limited-option settings such as Thailand.